Search

Krystal Biotech Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

356 -1.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

351.1

Max

362.86

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.2M

55M

Pardavimai

2.9M

119M

P/E

Sektoriaus vid.

43.421

57.366

Pelnas, tenkantis vienai akcijai

1.79

Pelno marža

45.938

Darbuotojai

295

EBITDA

2.9M

66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+13.05% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-257M

10B

Ankstesnė atidarymo kaina

357.02

Ankstesnė uždarymo kaina

356

Naujienos nuotaikos

By Acuity

14%

86%

26 / 340 reitingas Healthcare

Krystal Biotech Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-25 20:07; UTC

Krystal Biotech Inc shares are higher today, benefiting from easing Treasury yields and strong momentum, despite no specific company news driving the move.

2026-08-24 19:16; UTC

Krystal Biotech Inc's shares are lower today, continuing a decline since Friday. Market focus remains on upcoming economic events amid inflation concerns.

2026-08-21 21:01; UTC

Krystal Biotech shares are lower in after-market trading, reflecting a modest decline since Friday's close amid limited price fluctuations.

2026-08-20 21:01; UTC

Krystal Biotech Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average without any specific news to explain the rise.

2026-08-19 20:02; UTC

Correlated Moves

Shares rise amid positive momentum in biotechnology sector.

2026-08-14 19:46; UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

2026-08-13 19:46; UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

2026-08-12 20:52; UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

2026-08-11 21:01; UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

2026-08-07 19:26; UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

2026-08-06 19:26; UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

2026-08-05 19:52; UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

2026-08-04 20:04; UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

2026-08-03 23:06; UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

2026-07-31 23:06; UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

2026-07-30 19:39; UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

2026-07-29 20:04; UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

2026-07-28 20:03; UTC

Event
Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

2026-07-27 22:02; UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

2026-07-24 19:11; UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

2026-07-23 10:01; UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

2026-07-22 19:26; UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

2026-07-21 18:36; UTC

News
Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

2026-07-20 21:21; UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Akcijų palyginimas

Kainos pokytis

Krystal Biotech Inc Prognozė

Kainos tikslas

By TipRanks

13.05% į viršų

12 mėnesių prognozė

Vidutinis 402.67 USD  13.05%

Aukščiausias 474 USD

Žemiausias 361 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Krystal Biotech Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

26 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat